SG11201506357RA - Macrocyclic lrrk2 kinase inhibitors - Google Patents

Macrocyclic lrrk2 kinase inhibitors

Info

Publication number
SG11201506357RA
SG11201506357RA SG11201506357RA SG11201506357RA SG11201506357RA SG 11201506357R A SG11201506357R A SG 11201506357RA SG 11201506357R A SG11201506357R A SG 11201506357RA SG 11201506357R A SG11201506357R A SG 11201506357RA SG 11201506357R A SG11201506357R A SG 11201506357RA
Authority
SG
Singapore
Prior art keywords
kinase inhibitors
lrrk2 kinase
macrocyclic
macrocyclic lrrk2
inhibitors
Prior art date
Application number
SG11201506357RA
Inventor
Jan Hoflack
Petra Blom
Olivier Lavergne
Original Assignee
Ipsen Pharma Sas
Oncodesign Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas, Oncodesign Sa filed Critical Ipsen Pharma Sas
Publication of SG11201506357RA publication Critical patent/SG11201506357RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201506357RA 2013-03-15 2014-03-14 Macrocyclic lrrk2 kinase inhibitors SG11201506357RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305314 2013-03-15
EP13305311 2013-03-15
PCT/EP2014/055049 WO2014140235A1 (en) 2013-03-15 2014-03-14 Macrocyclic lrrk2 kinase inhibitors

Publications (1)

Publication Number Publication Date
SG11201506357RA true SG11201506357RA (en) 2015-09-29

Family

ID=50277239

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506357RA SG11201506357RA (en) 2013-03-15 2014-03-14 Macrocyclic lrrk2 kinase inhibitors

Country Status (19)

Country Link
US (1) US20160031905A1 (en)
EP (1) EP2970333B1 (en)
JP (1) JP2016510793A (en)
KR (1) KR20150129016A (en)
CN (1) CN105143232A (en)
AU (1) AU2014230485A1 (en)
BR (1) BR112015019873A2 (en)
CA (1) CA2904462A1 (en)
DK (1) DK2970333T3 (en)
EA (1) EA201591698A1 (en)
ES (1) ES2635021T3 (en)
HK (1) HK1219481A1 (en)
MX (1) MX2015011359A (en)
PL (1) PL2970333T3 (en)
PT (1) PT2970333T (en)
SG (1) SG11201506357RA (en)
TW (1) TW201444850A (en)
WO (1) WO2014140235A1 (en)
ZA (1) ZA201506327B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150133765A (en) * 2013-03-15 2015-11-30 온코디자인 에스.에이. Macrocyclic RIP2 kinase inhibitors
WO2016146651A1 (en) 2015-03-16 2016-09-22 Oncodesign Sa Macrocyclic activin-like receptor kinase inhibitors
CN113956269A (en) * 2018-04-16 2022-01-21 深圳市塔吉瑞生物医药有限公司 Di (hetero) aryl macrocycles for inhibiting protein kinase activity
AU2021214866A1 (en) * 2020-01-31 2022-09-22 Oncodesign Precision Medicine (OPM) Macrocyclic RIP2-kinase inhibitors
US11858940B2 (en) * 2020-03-21 2024-01-02 Arvinas Operations, Inc. Selective modulators of mutant LRRK2 proteolysis and associated methods of use
US11780851B2 (en) 2021-10-27 2023-10-10 H. Lundbeck A/S LRRK2 inhibitors
CN117425660A (en) * 2022-05-18 2024-01-19 上海翊石医药科技有限公司 Aromatic heterocyclic compound, intermediate thereof, pharmaceutical composition and application
CN117659043A (en) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 Macrocyclic imidazo [1,2-b ] pyridazine derivative and preparation method and application thereof
WO2024056775A1 (en) * 2022-09-15 2024-03-21 H. Lundbeck A/S Macrocyclic leucine-rich repeat kinase 2 (lrrk2) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201008134D0 (en) * 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
GB201015949D0 (en) * 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
PE20140927A1 (en) * 2011-04-21 2014-08-24 Origenis Gmbh HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
PL2760453T3 (en) * 2011-09-30 2016-11-30 Macrocyclic lrrk2 kinase inhibitors
JP6046728B2 (en) * 2011-09-30 2016-12-21 オンコデザイン エス.ア. Macrocyclic FLT3 kinase inhibitor

Also Published As

Publication number Publication date
JP2016510793A (en) 2016-04-11
CA2904462A1 (en) 2014-09-18
CN105143232A (en) 2015-12-09
HK1219481A1 (en) 2017-04-07
EP2970333B1 (en) 2017-05-03
EA201591698A1 (en) 2016-02-29
PT2970333T (en) 2017-08-01
PL2970333T3 (en) 2017-12-29
ES2635021T3 (en) 2017-10-02
ZA201506327B (en) 2017-02-22
TW201444850A (en) 2014-12-01
BR112015019873A2 (en) 2017-07-18
KR20150129016A (en) 2015-11-18
WO2014140235A1 (en) 2014-09-18
AU2014230485A1 (en) 2015-09-24
DK2970333T3 (en) 2017-08-21
US20160031905A1 (en) 2016-02-04
MX2015011359A (en) 2015-12-16
EP2970333A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
HK1220459A1 (en) Kinase inhibitors
ZA201603337B (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
HK1222387A1 (en) Arylpyrrolopyridine derived compounds as lrrk2 inhibitors lrrk2
HK1214813A1 (en) Rho kinase inhibitors rho
SG11201600062RA (en) Pyrimidine derivatives as kinase inhibitors
HK1211578A1 (en) Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1
HK1199838A1 (en) Macrocyclic lrrk2 kinase inhibitors lrrk2
HK1219104A1 (en) Kinase inhibitors
HK1219481A1 (en) Macrocyclic lrrk2 kinase inhibitors lrrk2
HK1219057A1 (en) Macrocyclic salt-inducible kinase inhibitors
EP3007689A4 (en) Non-selective kinase inhibitors
HK1213252A1 (en) Bicyclic dihydropyridone kinase inhibitors
ZA201701841B (en) Macrocyclic lrrk2 kinase inhibitors
HK1218263A1 (en) Macrocyclic rip2 kinase inhibitors rip2
HK1222539A1 (en) Pim kinase inhibitor combinations pim
EP2968995A4 (en) Inhibitors of lrrk2 kinase activity
EP2999472A4 (en) Aurora kinase inhibitors
IL244029A0 (en) Deoxycytidine kinase inhibitors
HK1213181A1 (en) Bicyclic oxa-lactam kinase inhibitors
GB201307155D0 (en) Kinase inhibitors
GB201304714D0 (en) Macrocyclic RIP2 Kinase inhibitors
GB201404570D0 (en) Macrocyclic kinase inhibitors
GB201404555D0 (en) Macrocyclic kinase inhibitors